|
|
1.
|
NANO SOMA
| Numéro d'application |
1690162 |
| Statut |
Enregistrée |
| Date de dépôt |
2022-07-22 |
| Date d'enregistrement |
2022-07-22 |
| Propriétaire |
NANORX INC. (USA)
|
| Classes de Nice ? |
05 - Produits pharmaceutiques, vétérinaires et hygièniques
|
Produits et services
Analgesic and muscle relaxant nutraceutical preparations;
anti-diabetic nutraceuticals; cardiovascular nutraceuticals;
nutraceutical preparations for the treatment of gout;
nutraceutical preparations and substances for the treatment
of gastro-intestinal diseases; nutraceutical preparations
and substances for the treatment of infectious diseases,
blood disorders, pain, inflammation, sepsis, alopecia,
obesity and cognitive disorders; nutraceutical preparations
and substances for the treatment of viral, metabolic,
endocrine, musculoskeletal, cardiovascular, cardiopulmonary,
genitourinary, sexual dysfunction, oncological,
hepatological, ophthalmic, respiratory, neurological,
gastrointestinal, hormonal, dermatological, psychiatric and
immune system related diseases and disorders; nutraceutical
preparations for inhalation for the treatment of pulmonary
hypertension; nutraceutical preparations for the prevention
and treatment of disorders of the nervous system, the immune
system, the cardio-vascular system, the metabolic system,
the respiratory system, the musculo-skeletal system, the
genitourinary system; nutraceutical preparations for the
treatment of inflammatory disorders; nutraceutical
preparations for use in dermatology, oncology, hematology
and in tissue and organ transplantation, in ophthalmology
and for gastroenterological disorders; nutraceutical
preparations for the prevention and treatment of ocular
disorders or diseases, bacteria-based diseases or disorders,
autoimmune diseases or disorders, kidney diseases or
disorders, and diabetes; nutraceutical preparations for the
prevention of diabetes; nutraceutical preparations for the
treatment of eye diseases and conditions; nutraceutical
preparations for the treatment of heart rhythm disorders;
nutraceutical preparations for the treatment of hormonal
disorders and the prevention of osteoporosis; nutraceutical
preparations for the treatment of infectious diseases;
nutraceutical preparations for the treatment of
hypertension; nutraceutical preparations for treating
allergic rhinitis and asthma; nutraceutical preparations for
treating diabetes; nutraceutical preparations for treating
skin disorders; nutraceutical preparations for use in
urology; nutraceutical preparations, namely, a blood
clotting aid and delivery system for use in human and
veterinary medicine; nutraceutical products for
ophthalmological use; nutraceutical products for the
treatment of bone diseases; nutraceutical products for the
treatment of joint disease; nutraceutical products for the
treatment of viral and infectious diseases; nutraceutical
preparations for the treatment of cancer; nutraceutical
products for treating respiratory diseases and asthma;
nutraceutical solutions used in dialysis; nutraceuticals,
namely, lipid lowering agents; plant extracts for medical,
veterinary and nutraceutical purposes; therapeutic
nutraceuticals for the treatment of obesity.
|
2.
|
METADICHOL
| Numéro d'application |
1675241 |
| Statut |
Enregistrée |
| Date de dépôt |
2022-04-22 |
| Date d'enregistrement |
2022-04-22 |
| Propriétaire |
NANORX INC. (USA)
|
| Classes de Nice ? |
05 - Produits pharmaceutiques, vétérinaires et hygièniques
|
Produits et services
Analgesic and muscle relaxant nutraceutical preparations;
anti-diabetic nutraceuticals; cardiovascular nutraceuticals;
nutraceutical preparations for the treatment of gout;
nutraceutical preparations and substances for the treatment
of gastro-intestinal diseases; nutraceutical preparations
and substances for the treatment of infectious diseases,
blood disorders, pain, inflammation, sepsis, alopecia,
obesity and cognitive disorders; nutraceutical preparations
and substances for the treatment of viral, metabolic,
endocrine, musculoskeletal, cardiovascular, cardiopulmonary,
genitourinary, sexual dysfunction, oncological,
hepatological, ophthalmic, respiratory, neurological,
gastrointestinal, hormonal, dermatological, psychiatric and
immune system related diseases and disorders; nutraceutical
preparations for inhalation for the treatment of pulmonary
hypertension; nutraceutical preparations for the prevention
and treatment of disorders of the nervous system, the immune
system, the cardio-vascular system, the metabolic system,
the respiratory system, the musculo-skeletal system, the
genitourinary system; nutraceutical preparations for the
treatment of inflammatory disorders; nutraceutical
preparations for use in dermatology, oncology, hematology
and in tissue and organ transplantation, in ophthalmology
and for gastroenterological disorders; nutraceutical
preparations for the prevention and treatment of ocular
disorders or diseases, bacteria-based diseases or disorders,
autoimmune diseases or disorders, kidney diseases or
disorders, and diabetes; nutraceutical preparations for the
prevention of diabetes; nutraceutical preparations for the
treatment of eye diseases and conditions; nutraceutical
preparations for the treatment of heart rhythm disorders;
nutraceutical preparations for the treatment of hormonal
disorders and the prevention of osteoporosis; nutraceutical
preparations for the treatment of infectious diseases;
nutraceutical preparations for the treatment of
hypertension; nutraceutical preparations for treating
allergic rhinitis and asthma; nutraceutical preparations for
treating diabetes; nutraceutical preparations for treating
skin disorders; nutraceutical preparations for use in
urology; nutraceutical preparations, namely, a blood
clotting aid and delivery system for use in human and
veterinary medicine; nutraceutical products for
ophthalmological use; nutraceutical products for the
treatment of bone diseases; nutraceutical products for the
treatment of joint disease; nutraceutical products for the
treatment of viral and infectious diseases; nutraceutical
preparations for the treatment of cancer; nutraceutical
products for treating respiratory diseases and asthma;
nutraceutical solutions used in dialysis; nutraceuticals,
namely, lipid lowering agents; plant extracts for medical,
veterinary and nutraceutical purposes; therapeutic
nutraceuticals for the treatment of obesity.
|
3.
|
METADICHOL
| Numéro d'application |
213297800 |
| Statut |
Enregistrée |
| Date de dépôt |
2021-09-13 |
| Date d'enregistrement |
2022-07-13 |
| Propriétaire |
Nanorx Inc. (USA)
|
| Classes de Nice ? |
05 - Produits pharmaceutiques, vétérinaires et hygièniques
|
Produits et services
(1) Analgesic and muscle relaxant nutraceutical preparations; Anti-diabetic nutraceuticals; Cardiovascular nutraceuticals; Nutraceutical preparations for the treatment of gout; Nutraceutical preparations and substances for the treatment of gastro-intestinal diseases; Nutraceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Nutraceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Nutraceutical preparations for inhalation for the treatment of pulmonary hypertension; Nutraceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; Nutraceutical preparations for the treatment of inflammatory disorders; Nutraceutical preparations for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Nutraceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Nutraceutical preparations for the prevention of diabetes; Nutraceutical preparations for the treatment of eye diseases and conditions; Nutraceutical preparations for the treatment of heart rhythm disorders; Nutraceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Nutraceutical preparations for the treatment of infectious diseases; Nutraceutical preparations for the treatment of hypertension; Nutraceutical preparations for treating allergic rhinitis and asthma; Nutraceutical preparations for treating diabetes; Nutraceutical preparations for treating skin disorders; Nutraceutical preparations for use in urology; Nutraceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Nutraceutical products for ophthalmological use; Nutraceutical products for the treatment of bone diseases; Nutraceutical products for the treatment of joint disease; Nutraceutical products for the treatment of viral and infectious diseases; Nutraceutical preparations for the treatment of cancer; Nutraceutical products for treating respiratory diseases and asthma; Nutraceutical solutions used in dialysis; Nutraceuticals, namely, lipid lowering agents; Plant extracts for medical, veterinary and nutraceutical purposes for maintaining and boosting the immune system; Therapeutic nutraceuticals for the treatment of obesity; Analgesic and muscle relaxant pharmaceutical preparations; Anti-diabetic pharmaceuticals; Cardiovascular pharmaceuticals; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system, for the treatment of inflammatory disorders, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the prevention of diabetes; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of hypertension; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in urology; Pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Pharmaceutical products for ophthalmological use; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical solutions used in dialysis; Pharmaceuticals, namely, lipid lowering agents; Plant extracts for medical, veterinary and pharmaceutical purposes for maintaining and boosting the immune system; Therapeutic pharmaceutical for the treatment of obesity
|
4.
|
NANO SOMA
| Numéro d'application |
213298300 |
| Statut |
Enregistrée |
| Date de dépôt |
2021-09-13 |
| Date d'enregistrement |
2022-07-13 |
| Propriétaire |
Nanorx Inc. (USA)
|
| Classes de Nice ? |
05 - Produits pharmaceutiques, vétérinaires et hygièniques
|
Produits et services
(1) Nutraceuticals for use as a dietary supplement for boosting the immune system
|
5.
|
NANO SOMA
| Numéro de série |
90896879 |
| Statut |
Enregistrée |
| Date de dépôt |
2021-08-23 |
| Date d'enregistrement |
2022-09-13 |
| Propriétaire |
NANORX INC. ()
|
| Classes de Nice ? |
05 - Produits pharmaceutiques, vétérinaires et hygièniques
|
Produits et services
Nutraceuticals for use as a dietary supplement
|
6.
|
NANO SOMA
| Numéro d'application |
018537187 |
| Statut |
Enregistrée |
| Date de dépôt |
2021-08-19 |
| Date d'enregistrement |
2021-12-15 |
| Propriétaire |
Nanorx, Inc. (USA)
|
| Classes de Nice ? |
05 - Produits pharmaceutiques, vétérinaires et hygièniques
|
Produits et services
Nutraceuticals for use as a dietary supplement.
|
7.
|
METADICHOL
| Numéro d'application |
018535307 |
| Statut |
Enregistrée |
| Date de dépôt |
2021-08-19 |
| Date d'enregistrement |
2021-12-24 |
| Propriétaire |
Nanorx, Inc. (USA)
|
| Classes de Nice ? |
05 - Produits pharmaceutiques, vétérinaires et hygièniques
|
Produits et services
Analgesic and muscle relaxant nutraceutical preparations; anti-diabetic nutraceuticals; Cardiovascular nutraceuticals; Nutraceutical preparations for the treatment of gout; Nutraceutical preparations and substances for the treatment of gastro-intestinal diseases; Nutraceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Nutraceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Nutraceutical preparations for inhalation for the treatment of pulmonary hypertension; Nutraceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; Nutraceutical preparations for the treatment of inflammatory disorders; Nutraceutical preparations for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Nutraceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Nutraceutical preparations for the prevention of diabetes; Nutraceutical preparations for the treatment of eye diseases and conditions; Nutraceutical preparations for the treatment of heart rhythm disorders; Nutraceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Nutraceutical preparations for the treatment of infectious diseases; Nutraceutical preparations for the treatment of hypertension; Nutraceutical preparations for treating allergic rhinitis and asthma; Nutraceutical preparations for treating diabetes; Nutraceutical preparations for treating skin disorders; Nutraceutical preparations for use in urology; Nutraceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Nutraceutical products for ophthalmological use; Nutraceutical products for the treatment of bone diseases; Nutraceutical products for the treatment of joint disease; Nutraceutical products for the treatment of viral and infectious diseases; Nutraceutical preparations for the treatment of cancer; Nutraceutical products for treating respiratory diseases and asthma; Nutraceutical solutions used in dialysis; Nutraceuticals, namely, lipid lowering agents; Plant extracts for medical, veterinary and nutraceutical purposes; Therapeutic nutraceuticals for the treatment of obesity.
|
8.
|
NANO-OJAS
| Numéro d'application |
018537185 |
| Statut |
Enregistrée |
| Date de dépôt |
2021-08-19 |
| Date d'enregistrement |
2021-12-24 |
| Propriétaire |
Nanorx, Inc. (USA)
|
| Classes de Nice ? |
05 - Produits pharmaceutiques, vétérinaires et hygièniques
|
Produits et services
Analgesic and muscle relaxant nutraceutical preparations; Anti-diabetic nutraceuticals; Cardiovascular nutraceuticals; Nutraceutical preparations for the treatment of gout; Nutraceutical preparations and substances for the treatment of gastro-intestinal diseases; Nutraceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Nutraceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Nutraceutical preparations for inhalation for the treatment of pulmonary hypertension; Nutraceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; Nutraceutical preparations for the treatment of inflammatory disorders; Nutraceutical preparations for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Nutraceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Nutraceutical preparations for the prevention of diabetes; Nutraceutical preparations for the treatment of eye diseases and conditions; Nutraceutical preparations for the treatment of heart rhythm disorders; Nutraceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Nutraceutical preparations for the treatment of infectious diseases; Nutraceutical preparations for the treatment of hypertension; Nutraceutical preparations for treating allergic rhinitis and asthma; Nutraceutical preparations for treating diabetes; Nutraceutical preparations for treating skin disorders; Nutraceutical preparations for use in urology; Nutraceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Nutraceutical products for ophthalmological use; Nutraceutical products for the treatment of bone diseases; Nutraceutical products for the treatment of joint disease; Nutraceutical products for the treatment of viral and infectious diseases; Nutraceutical preparations for the treatment of cancer; Nutraceutical products for treating respiratory diseases and asthma; Nutraceutical solutions used in dialysis; Nutraceuticals, namely, lipid lowering agents; Plant extracts for medical, veterinary and nutraceutical purposes; Therapeutic nutraceuticals for the treatment of obesity.
|
9.
|
NANO-OJAS
| Numéro de série |
87073835 |
| Statut |
Enregistrée |
| Date de dépôt |
2016-06-16 |
| Date d'enregistrement |
2016-12-20 |
| Propriétaire |
NANORX INC. (USA)
|
| Classes de Nice ? |
05 - Produits pharmaceutiques, vétérinaires et hygièniques
|
Produits et services
Analgesic and muscle relaxant nutraceutical preparations; Anti-diabetic nutraceuticals; Cardiovascular nutraceuticals; Nutraceutical preparations for the treatment of gout; Nutraceutical preparations and substances for the treatment of gastro-intestinal diseases; Nutraceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Nutraceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Nutraceutical preparations for inhalation for the treatment of pulmonary hypertension; Nutraceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; Nutraceutical preparations for the treatment of inflammatory disorders; Nutraceutical preparations for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Nutraceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Nutraceutical preparations for the prevention of diabetes; Nutraceutical preparations for the treatment of eye diseases and conditions; Nutraceutical preparations for the treatment of heart rhythm disorders; Nutraceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Nutraceutical preparations for the treatment of infectious diseases; Nutraceutical preparations for the treatment of hypertension; Nutraceutical preparations for treating allergic rhinitis and asthma; Nutraceutical preparations for treating diabetes; Nutraceutical preparations for treating skin disorders; Nutraceutical preparations for use in urology; Nutraceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Nutraceutical products for ophthalmological use; Nutraceutical products for the treatment of bone diseases; Nutraceutical products for the treatment of joint disease; Nutraceutical products for the treatment of viral and infectious diseases; Nutraceutical preparations for the treatment of cancer; Nutraceutical products for treating respiratory diseases and asthma; Nutraceutical solutions used in dialysis; Nutraceuticals, namely, lipid lowering agents; Plant extracts for medical, veterinary and nutraceutical purposes; Therapeutic nutraceuticals for the treatment of obesity
|
10.
|
METADICHOL
| Numéro de série |
87017926 |
| Statut |
Enregistrée |
| Date de dépôt |
2016-04-28 |
| Date d'enregistrement |
2016-12-20 |
| Propriétaire |
NANORX INC. ()
|
| Classes de Nice ? |
05 - Produits pharmaceutiques, vétérinaires et hygièniques
|
Produits et services
Analgesic and muscle relaxant nutraceutical preparations; Anti-diabetic nutraceuticals; Cardiovascular nutraceuticals; Nutraceutical preparations for the treatment of gout; Nutraceutical preparations and substances for the treatment of gastro-intestinal diseases; Nutraceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Nutraceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Nutraceutical preparations for inhalation for the treatment of pulmonary hypertension; Nutraceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; Nutraceutical preparations for the treatment of inflammatory disorders; Nutraceutical preparations for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Nutraceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Nutraceutical preparations for the prevention of diabetes; Nutraceutical preparations for the treatment of eye diseases and conditions; Nutraceutical preparations for the treatment of heart rhythm disorders; Nutraceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Nutraceutical preparations for the treatment of infectious diseases; Nutraceutical preparations for the treatment of hypertension; Nutraceutical preparations for treating allergic rhinitis and asthma; Nutraceutical preparations for treating diabetes; Nutraceutical preparations for treating skin disorders; Nutraceutical preparations for use in urology; Nutraceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Nutraceutical products for ophthalmological use; Nutraceutical products for the treatment of bone diseases; Nutraceutical products for the treatment of joint disease; Nutraceutical products for the treatment of viral and infectious diseases; Nutraceutical preparations for the treatment of cancer; Nutraceutical products for treating respiratory diseases and asthma; Nutraceutical solutions used in dialysis; Nutraceuticals, namely, lipid lowering agents; Plant extracts for medical, veterinary and nutraceutical purposes; Therapeutic nutraceuticals for the treatment of obesity
|
11.
|
METADICHOL.RTM. LIQUID AND GEL NANOPARTICLE FORMULATIONS
| Numéro de document |
02894370 |
| Statut |
Délivré - en vigueur |
| Date de dépôt |
2014-03-11 |
| Date de disponibilité au public |
2014-09-25 |
| Date d'octroi |
2016-01-12 |
| Propriétaire |
NANORX, INC. (USA)
|
| Inventeur(s) |
Raghavan, Palayakotai R.
|
Abrégé
The present invention provides methods of regulating physiological and metabolic parameters and of treating diseases by administering metadichol to a subject in need of such regulation and/or treatment. Metadichol can be administered as a liquid or gel formulation.
Classes IPC ?
- A61K 9/10 - DispersionsÉmulsions
- A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
- A61K 31/045 - Composés hydroxylés, p. ex. alcoolsLeurs sels, p. ex. alcoolates
- A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
- A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
- A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
|
12.
|
METADICHOL R LIQUID AND GEL NANOPARTICLE FORMULATIONS
| Numéro d'application |
US2014023777 |
| Numéro de publication |
2014/150609 |
| Statut |
Délivré - en vigueur |
| Date de dépôt |
2014-03-11 |
| Date de publication |
2014-09-25 |
| Propriétaire |
NANORX, INC. (USA)
|
| Inventeur(s) |
Raghavan, Palayakotai, R.
|
Abrégé
The present invention provides methods of regulating physiological and metabolic parameters and of treating diseases by administering metadichol to a subject in need of such regulation and/or treatment. Metadichol can be administered as a liquid or gel formulation.
Classes IPC ?
- A61K 31/045 - Composés hydroxylés, p. ex. alcoolsLeurs sels, p. ex. alcoolates
- A61K 9/50 - Microcapsules
- A61K 9/40 - Revêtements organiques contenant des protéines ou leurs dérivés contenant de la gélatine
- A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
|
13.
|
Metadichol® liquid and gel nanoparticle formulations
| Numéro d'application |
14205243 |
| Numéro de brevet |
09006292 |
| Statut |
Délivré - en vigueur |
| Date de dépôt |
2014-03-11 |
| Date de la première publication |
2014-09-18 |
| Date d'octroi |
2015-04-14 |
| Propriétaire |
NanoRx, Inc. (USA)
|
| Inventeur(s) |
Raghavan, Palayakotai R.
|
Abrégé
The present invention provides methods of regulating physiological and metabolic parameters and of treating diseases by administering metadichol to a subject in need of such regulation and/or treatment. Metadichol can be administered as a liquid or gel formulation.
Classes IPC ?
- A61K 31/045 - Composés hydroxylés, p. ex. alcoolsLeurs sels, p. ex. alcoolates
- B82Y 30/00 - Nanotechnologie pour matériaux ou science des surfaces, p. ex. nanocomposites
- A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
- A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
|
14.
|
POLICOSANOL NANOPARTICLES
| Numéro de document |
02844073 |
| Statut |
Délivré - en vigueur |
| Date de dépôt |
2011-08-16 |
| Date de disponibilité au public |
2012-03-01 |
| Date d'octroi |
2015-10-13 |
| Propriétaire |
NANORX, INC. (USA)
|
| Inventeur(s) |
Raghavan, Palayakotai R.
|
Abrégé
The present invention provides nanoparticulate policosanol, and octacosanol formulations including these particles, as a well as methods of using the particles and formulations for treatment and prophylaxis of various diseases and conditions.
Classes IPC ?
- A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
- A61K 31/045 - Composés hydroxylés, p. ex. alcoolsLeurs sels, p. ex. alcoolates
- A61P 3/06 - Antihyperlipémiants
- A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
|
15.
|
POLICOSANOL NANOPARTICLES
| Numéro d'application |
US2011047951 |
| Numéro de publication |
2012/027159 |
| Statut |
Délivré - en vigueur |
| Date de dépôt |
2011-08-16 |
| Date de publication |
2012-03-01 |
| Propriétaire |
NANORX, INC. (USA)
|
| Inventeur(s) |
Raghavan, Palayakotai, R.
|
Abrégé
The present invention provides nanoparticulate policosanol, and octacosanol formulations including these particles, as a well as methods of using the particles and formulations for treatment and prophylaxis of various diseases and conditions.
Classes IPC ?
- A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
|
16.
|
Policosanol nanoparticles
| Numéro d'application |
13211132 |
| Numéro de brevet |
09034383 |
| Statut |
Délivré - en vigueur |
| Date de dépôt |
2011-08-16 |
| Date de la première publication |
2012-02-23 |
| Date d'octroi |
2015-05-19 |
| Propriétaire |
NanoRx, Inc. (USA)
|
| Inventeur(s) |
Raghavan, Palayakotai R.
|
Abrégé
The present invention provides nanoparticulate policosanol, and octacosanol formulations including these particles, as a well as methods of using the particles and formulations for treatment and prophylaxis of various diseases and conditions.
Classes IPC ?
- A61K 31/045 - Composés hydroxylés, p. ex. alcoolsLeurs sels, p. ex. alcoolates
- A61K 31/355 - Tocophérols, p. ex. vitamine E
- B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p. ex. génie protéique ou administration de médicaments
- A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
- A61K 9/51 - Nanocapsules
|
17.
|
POLICOSANOL NANOPARTICLES
| Numéro de document |
02788777 |
| Statut |
Délivré - en vigueur |
| Date de dépôt |
2010-01-21 |
| Date de disponibilité au public |
2010-08-26 |
| Date d'octroi |
2015-02-17 |
| Propriétaire |
NANORX, INC. (USA)
|
| Inventeur(s) |
Raghavan, Palayakotai R.
|
Abrégé
The present invention provides nanoparticulate policosanol, formulations including these particles, as a well as methods of using the particles and formulations for treatment and prophylaxis of various diseases and conditions.
Classes IPC ?
- A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
- A61K 31/045 - Composés hydroxylés, p. ex. alcoolsLeurs sels, p. ex. alcoolates
|
18.
|
POLICOSANOL NANOPARTICLES
| Numéro d'application |
US2010021684 |
| Numéro de publication |
2010/096231 |
| Statut |
Délivré - en vigueur |
| Date de dépôt |
2010-01-21 |
| Date de publication |
2010-08-26 |
| Propriétaire |
NANORX, INC. (USA)
|
| Inventeur(s) |
Raghavan, Palayakotai, R.
|
Abrégé
The present invention provides nanoparticulate policosanol, formulations including these particles, as a well as methods of using the particles and formulations for treatment and prophylaxis of various diseases and conditions.
Classes IPC ?
- A61K 31/56 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes
- A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
|
19.
|
Policosanol nanoparticles
| Numéro d'application |
12691706 |
| Numéro de brevet |
08722093 |
| Statut |
Délivré - en vigueur |
| Date de dépôt |
2010-01-21 |
| Date de la première publication |
2010-08-26 |
| Date d'octroi |
2014-05-13 |
| Propriétaire |
NanoRx, Inc. (USA)
|
| Inventeur(s) |
Raghavan, Palayakotai R.
|
Abrégé
The present invention provides nanoparticulate policosanol, formulations including these particles, as a well as methods of using the particles and formulations for treatment and prophylaxis of various diseases and conditions.
Classes IPC ?
- A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
- A61K 9/50 - Microcapsules
- A61K 31/045 - Composés hydroxylés, p. ex. alcoolsLeurs sels, p. ex. alcoolates
|
|